Baozhen Ke

1.8k total citations · 1 hit paper
12 papers, 457 citations indexed

About

Baozhen Ke is a scholar working on Molecular Biology, Immunology and Nephrology. According to data from OpenAlex, Baozhen Ke has authored 12 papers receiving a total of 457 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 6 papers in Immunology and 3 papers in Nephrology. Recurrent topics in Baozhen Ke's work include Complement system in diseases (3 papers), Protein Degradation and Inhibitors (3 papers) and Acute Myeloid Leukemia Research (2 papers). Baozhen Ke is often cited by papers focused on Complement system in diseases (3 papers), Protein Degradation and Inhibitors (3 papers) and Acute Myeloid Leukemia Research (2 papers). Baozhen Ke collaborates with scholars based in United States, China and Taiwan. Baozhen Ke's co-authors include Michael Braun, Travis J. Hollmann, Scott E. Wenderfer, Rick A. Wetsel, Li-Chuan Chan, Jung-Mao Hsu, Mien‐Chie Hung, Heng‐Huan Lee, Chunru Lin and Gabriel N. Hortobágyi and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Blood.

In The Last Decade

Baozhen Ke

11 papers receiving 456 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis

2021 255 citations Zhou Jiang, Seung-Oe Lim et al. Journal of Clinical Investigation profile →

Peers

Countries citing papers authored by Baozhen Ke

Since Specialization

Citations

This map shows the geographic impact of Baozhen Ke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Baozhen Ke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Baozhen Ke more than expected).

Fields of papers citing papers by Baozhen Ke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Baozhen Ke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Baozhen Ke. The network helps show where Baozhen Ke may publish in the future.

Co-authorship network of co-authors of Baozhen Ke

This figure shows the co-authorship network connecting the top 25 collaborators of Baozhen Ke. A scholar is included among the top collaborators of Baozhen Ke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Baozhen Ke. Baozhen Ke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	Restoring p53 wild-type conformation in TP53 -Y220C–mutant acute myeloid leukemia 2025 ·Blood ·(unknown), Po Yee Mak, Edward Ayoub, Xiaogang Wu, Baozhen Ke, (unknown), P. Andrew Futreal, (unknown), (unknown), Steffen Boettcher, Courtney D. DiNardo, Anna M. Puzio‐Kuter, Masha V. Poyurovsky, (unknown), Michael Andreeff	0
2	Targeting Co-Regulatory Feedback Loop of MYC and GSPT1 By MYC/GSPT1 Dual Degradation Is Synthetic Lethal in Combination with Ven/Aza in TP53 Mutant Acute Myeloid Leukemia Stem and Progenitor Cells 2024 ·Blood ·(unknown), Hideaki Mizuno, Edward Ayoub, Eiji Sugihara, (unknown), (unknown), (unknown), Po Yee Mak, Baozhen Ke, Bing Z. Carter, Abhishek Maiti, Liandong Ma, Michael Andreeff	1
3	Inhibition of Galectin-9 sensitizes tumors to anthracycline treatment via inducing antitumor immunity 2023 ·International Journal of Biological Sciences ·Xian Wen Sun, Wei‐Jan Wang, (unknown), Ri‐Yao Yang, Wan‐Jou Shen, Linlin Sun, Jung-Mao Hsu, Li-Chuan Chan, Chia-Wei Li, Weiya Xia, Baozhen Ke, Guo‐Dong Yao, Ke-Bin Huang, Pei‐Chih Lee, Paul Koller, Mien‐Chie Hung	8
4	Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma 2023 ·Journal of Biological Chemistry ·Xuan Hong, Min‐Tsang Hsieh, (unknown), Hui‐Yi Lin, (unknown), (unknown), Wei‐Chung Cheng, Baozhen Ke, (unknown), Chih‐Ying Wu, (unknown), Meei‐Maan Wu, Kuo‐Yen Huang, Pan‐Chyr Yang, Sheng‐Chu Kuo, Mien‐Chie Hung, Pei‐Chih Lee	6
5	ERK1/2 Inhibition Overcomes Resistance to Venetoclax in AML By Inhibiting Drp1 Dependent Mitochondrial Fission 2023 ·Blood ·Priyanka Sharma, (unknown), Sujan Piya, Baozhen Ke, Natalia Baran, (unknown), Muharrem Müftüoğlu, (unknown), Qi Zhang, Joanne M. Munck, (unknown), Martin Sims, Bing Z. Carter, Venkata Lokesh Battula, Michael Andreeff, Gautam Borthakur	1
6	Selective Targeting of TP53-Y220C Mutant AML By PC14586 Results in TP53 Wild-Type Conformation and Synergistical Apoptosis Induction By Concomitant Inhibition of Xpo-1, MDM2, or Bcl-2 2023 ·Blood ·Bing Z. Carter, Po Yee Mak, Baozhen Ke, Yuki Nishida, Steffen Boettcher, (unknown), (unknown), Courtney D. DiNardo, Anna M. Puzio‐Kuter, Arnold J. Levine, Michael Andreeff	7
7	Calibrated Release IL15 Bivalent CD33 and/or FLT3 and NOT Emcn Logic Gated Gene Circuit CAR-NK Cell Therapy (SENTI-202) in Venetoclax Resistant Patient Derived Xenograft Acute Myeloid Leukemia Models 2023 ·Blood ·Muharrem Müftüoğlu, (unknown), Li Li, (unknown), (unknown), Ran Zhao, Baozhen Ke, Hiroki Akiyama, Po Yee Mak, Bing Z. Carter, Han‐Xiang Deng, (unknown), Brian S. Garrison, (unknown), Michael Andreeff	1
8	TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis breakdown → 2021 ·Journal of Clinical Investigation ·Zhou Jiang, Seung-Oe Lim, Meisi Yan, Jennifer L. Hsu, Jun Yao, Yongkun Wei, Sam S. Chang, Hirohito Yamaguchi, Heng‐Huan Lee, Baozhen Ke, Jung-Mao Hsu, Li-Chuan Chan, Gabriel N. Hortobágyi, Liuqing Yang, Chunru Lin, Dihua Yu, Mien‐Chie Hung	255
9	C3a receptor deficiency accelerates the onset of renal injury in the MRL/lpr mouse 2009 ·Molecular Immunology ·Scott E. Wenderfer, Hongyu Wang, Baozhen Ke, Rick A. Wetsel, Michael Braun	37
10	Proteomic Profiling of Urinary Protein Excretion in the Factor H-Deficient Mouse 2006 ·American Journal of Nephrology ·Michael Braun, Li Li, Baozhen Ke, William P. Dubinsky, Matthew C. Pickering, Jui‐Yoa Chang	14
11	C5a Receptor Deficiency Attenuates T Cell Function and Renal Disease in MRLlpr Mice 2005 ·Journal of the American Society of Nephrology ·Scott E. Wenderfer, Baozhen Ke, Travis J. Hollmann, Rick A. Wetsel, Hui Y. Lan, Michael Braun	59
12	Renal Expression of the C3a Receptor and Functional Responses of Primary Human Proximal Tubular Epithelial Cells 2004 ·The Journal of Immunology ·Michael Braun, Rose Y. Reins, (unknown), Travis J. Hollmann, Ranjan Dutta, (unknown), Ba-Bie Teng, Baozhen Ke	68

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact